T1	PROC 1 12	Tratamiento
#1	AnnotatorNotes T1	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T2	CHEM 27 38	benznidazol
#2	AnnotatorNotes T2	C0053230; benznidazole; Organic Chemical · Pharmacologic Substance
T3	CHEM 41 55	ácido tióctico
#3	AnnotatorNotes T3	C0023791; thioctic acid; Organic Chemical · Pharmacologic Substance · Vitamin
T4	DISO 1285 1306	experiencias adversas
#4	AnnotatorNotes T4	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T5	PROC 813 836	suspender la medicación
#5	AnnotatorNotes T5	C0850893; stop medication; Therapeutic or Preventive Procedure
T6	PROC 148 174	tratamiento oral combinado
#6	AnnotatorNotes T6	C0009429; Combined Modality Therapy; Therapeutic or Preventive Procedure + C1273553; Oral administration of treatment; Therapeutic or Preventive Procedure
T7	CHEM 179 193	ácido tióctico
#7	AnnotatorNotes T7	C0023791; thioctic acid; Organic Chemical · Pharmacologic Substance · Vitamin
T8	CHEM 290 292	BZ
#8	AnnotatorNotes T8	C0053230; benznidazole; Organic Chemical · Pharmacologic Substance
T9	CHEM 551 553	BZ
#9	AnnotatorNotes T9	C0053230; benznidazole; Organic Chemical · Pharmacologic Substance
T10	DISO 228 247	efectos secundarios
#10	AnnotatorNotes T10	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T11	PROC 261 272	tratamiento
#11	AnnotatorNotes T11	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T12	DISO 307 339	infectados con Trypanosoma cruzi
#12	AnnotatorNotes T12	C0041234; Chagas Disease; Disease or Syndrome
T13	PROC 416 423	placebo
#13	AnnotatorNotes T13	C0032042; Placebos; Therapeutic or Preventive Procedure
T14	CHEM 864 866	BZ
#14	AnnotatorNotes T14	C0053230; benznidazole; Organic Chemical · Pharmacologic Substance
T15	CHEM 1573 1575	BZ
#15	AnnotatorNotes T15	C0053230; benznidazole; Organic Chemical · Pharmacologic Substance
T16	PROC 661 672	tratamiento
#16	AnnotatorNotes T16	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T17	PROC 775 786	tratamiento
#17	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	CHEM 826 836	medicación
#18	AnnotatorNotes T18	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T19	DISO 921 935	efecto adverso
#19	AnnotatorNotes T19	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T20	DISO 1048 1081	manifestaciones clínicas adversas
#20	AnnotatorNotes T20	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T21	DISO 1090 1111	exantema morbiliforme
#21	AnnotatorNotes T21	C0234918; Morbilliform rash; Finding
T22	DISO 1119 1126	prurito
#22	AnnotatorNotes T22	C0033774; Pruritus; Sign or Symptom
T23	DISO 1136 1143	cefalea
#23	AnnotatorNotes T23	C0018681; Headache; Sign or Symptom
T24	DISO 1150 1163	epigastralgia
#24	AnnotatorNotes T24	C0232493; Epigastric pain; Sign or Symptom
T25	DISO 1172 1178	fiebre
#25	AnnotatorNotes T25	C0015967; Fever; Sign or Symptom
T26	DISO 1187 1194	astenia
#26	AnnotatorNotes T26	C0004093; Asthenia; Sign or Symptom
T27	DISO 1203 1210	náuseas
#27	AnnotatorNotes T27	C0027497; Nausea; Sign or Symptom
T28	DISO 1219 1227	mialgias
#28	AnnotatorNotes T28	C0231528; Myalgia; Sign or Symptom
T29	DISO 1236 1243	vómitos
#29	AnnotatorNotes T29	C0042963; Vomiting; Sign or Symptom
T30	CHEM 1452 1466	ácido tióctico
#30	AnnotatorNotes T30	C0023791; thioctic acid; Organic Chemical · Pharmacologic Substance · Vitamin
T31	PROC 1479 1487	prevenir
#31	AnnotatorNotes T31	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T32	DISO 1492 1523	manifestaciones de intolerancia
#32	AnnotatorNotes T32	C0277585; Intolerance to drug; Pathologic Function | C0559546; adverse reactions; Pathologic Function (?)
T33	CHEM 1531 1537	agente
#33	AnnotatorNotes T33	C0450442; Agent; Chemical Viewed Functionally
T34	DISO 1614 1624	infectados
#34	AnnotatorNotes T34	C0009450; Communicable Diseases; Disease or Syndrome | C0439663; Infected; Finding | C3714514; Infection; Pathologic Function
T35	PROC 1665 1688	tratamiento ambulatorio
#35	AnnotatorNotes T35	C0002423; ambulatory care services; Health Care Activity (?)
T36	PROC 71 127	ensayo clínico controlado, multicéntrico, a triple ciego
#36	AnnotatorNotes T36	C0681867; Controlled Study; Research Activity + C1883398; Triple Blind Study; Research Activity + C1096776; Multicenter Study; Research Activity
T37	CHEM 277 288	benznidazol
#37	AnnotatorNotes T37	C0053230; benznidazole; Organic Chemical · Pharmacologic Substance
T38	DISO 16 22	Chagas
#38	AnnotatorNotes T38	C0041234; Chagas Disease; Disease or Syndrome
T39	Route 160 164	oral
#39	AnnotatorNotes T39	C1527415; Oral Route of Drug administration; Functional Concept
T40	LIVB 297 306	pacientes
#40	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T41	LIVB 322 339	Trypanosoma cruzi
#41	AnnotatorNotes T41	C0041221; Trypanosoma cruzi; Eukaryote
T42	Route 433 441	vía oral
#42	AnnotatorNotes T42	C1527415; Oral Route of Drug administration; Functional Concept
T43	Dose 453 462	50-100 mg
T45	Dose 565 572	5 mg/kg
T46	Frequency 572 576	/día
T47	Duration 581 588	30 días
T48	LIVB 696 705	pacientes
#43	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T49	Age 717 735	entre 15 y 44 años
T50	LIVB 753 762	pacientes
#44	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	LIVB 886 894	personas
#45	AnnotatorNotes T51	C0027361; Persons; Population Group
T55	LIVB 1422 1431	pacientes
#46	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T56	Neg_cue 1467 1469	no
T57	Frequency 1588 1595	mensual
T58	LIVB 1604 1613	pacientes
#47	AnnotatorNotes T58	C0030705; Patients; Patient or Disabled Group
T60	Frequency 463 466	día
T63	Duration 621 645	los días 10, 20, 37 y 52
T44	PROC 365 382	asignados al azar
#48	AnnotatorNotes T44	C0034656; Randomization; Research Activity
T52	Dose 469 474;488 497	dosis variables
T53	CONC 509 530	período pre-inducción
#49	AnnotatorNotes T53	C3274438; Run-in Period; Temporal Concept
T54	Neg_cue 505 508	sin
T59	PROC 605 617	evaluaciones
#50	AnnotatorNotes T59	C5235447; Safety Monitoring; Research Activity (?)
T61	Neg_cue 999 1006	ninguno
T62	Quantifier_or_Qualifier 1036 1041	grave
T64	Observation 1651 1661	adherencia
#51	AnnotatorNotes T64	C2364172; Adherence To Medication Regime; Finding
T65	CHEM 195 197	AT
#52	AnnotatorNotes T65	C0023791; thioctic acid; Organic Chemical · Pharmacologic Substance · Vitamin
T66	CHEM 426 428	AT
#53	AnnotatorNotes T66	C0023791; thioctic acid; Organic Chemical · Pharmacologic Substance · Vitamin
A1	Assertion T31 Negated
R1	Used_for Arg1:T2 Arg2:T1
R2	Combined_with Arg1:T2 Arg2:T3
R3	Has_Route_or_Mode Arg1:T7 Arg2:T39
R4	Used_for Arg1:T7 Arg2:T6
R6	Used_for Arg1:T8 Arg2:T11
R7	Used_for Arg1:T37 Arg2:T11
R8	Experiences Arg1:T40 Arg2:T11
R9	Causes Arg1:T41 Arg2:T12
R10	Experiences Arg1:T40 Arg2:T12
R11	Combined_with Arg1:T7 Arg2:T37
R12	Combined_with Arg1:T7 Arg2:T8
R13	Has_Route_or_Mode Arg1:T13 Arg2:T42
R14	Negation Arg1:T54 Arg2:T53
A2	Assertion T53 Negated
R15	Has_Dose_or_Strength Arg1:T9 Arg2:T45
R16	Has_Frequency Arg1:T9 Arg2:T46
R17	Has_Duration_or_Interval Arg1:T9 Arg2:T47
R18	Before Arg1:T16 Arg2:T59
R19	Overlap Arg1:T59 Arg2:T63
R20	Has_Age Arg1:T48 Arg2:T49
R21	Experiences Arg1:T50 Arg2:T17
R22	Experiences Arg1:T50 Arg2:T5
R24	Experiences Arg1:T51 Arg2:T19
A3	Assertion T62 Negated
R25	Negation Arg1:T61 Arg2:T62
R26	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T62
R27	Experiences Arg1:T55 Arg2:T4
R28	Negation Arg1:T56 Arg2:T31
R29	Used_for Arg1:T30 Arg2:T31
R30	Combined_with Arg1:T30 Arg2:T33
R31	Causes Arg1:T33 Arg2:T32
R32	Has_Frequency Arg1:T15 Arg2:T57
R33	Experiences Arg1:T58 Arg2:T34
R34	Experiences Arg1:T58 Arg2:T35
R35	Experiences Arg1:T58 Arg2:T15
R5	Causes Arg1:T37 Arg2:T10
R37	Causes Arg1:T8 Arg2:T10
R38	Experiences Arg1:T40 Arg2:T10
R39	Experiences Arg1:T40 Arg2:T6
R40	Has_Dose_or_Strength Arg1:T13 Arg2:T43
R41	Has_Frequency Arg1:T13 Arg2:T60
R42	Has_Dose_or_Strength Arg1:T13 Arg2:T52
R43	Has_Duration_or_Interval Arg1:T13 Arg2:T47
R44	Combined_with Arg1:T13 Arg2:T9
R45	Used_for Arg1:T14 Arg2:T17
R46	Overlap Arg1:T10 Arg2:T11
R47	Used_for Arg1:T18 Arg2:T17
R49	Has_Route_or_Mode Arg1:T65 Arg2:T39
R50	Has_Route_or_Mode Arg1:T66 Arg2:T42
R51	Has_Dose_or_Strength Arg1:T66 Arg2:T43
R52	Has_Frequency Arg1:T66 Arg2:T60
R54	Has_Duration_or_Interval Arg1:T66 Arg2:T47
R55	Combined_with Arg1:T66 Arg2:T9
R56	Overlap Arg1:T5 Arg2:T14
R23	Combined_with Arg1:T65 Arg2:T37
R57	Combined_with Arg1:T65 Arg2:T8
R48	Used_for Arg1:T65 Arg2:T6
R53	Has_Dose_or_Strength Arg1:T66 Arg2:T52
T67	CONC 1310 1317	difirió
A4	Assertion T67 Negated
#54	AnnotatorNotes T67	C1705241; Delta (difference); Quantitative Concept
T68	Neg_cue 1307 1309	no
R58	Negation Arg1:T68 Arg2:T67	
T69	Quantifier_or_Qualifier 1318 1336	significativamente
A5	Assertion T69 Negated
#55	AnnotatorNotes T69	C0237881; Statistical Significance; Quantitative Concept
R59	Negation Arg1:T68 Arg2:T69	
R60	Has_Quantifier_or_Qualifier Arg1:T67 Arg2:T69	
R61	Before Arg1:T44 Arg2:T13	
R62	Before Arg1:T44 Arg2:T66	
R63	Used_for Arg1:T18 Arg2:T5	
#56	AnnotatorNotes T62	C1547227; Severe - Severity of Illness Code; Intellectual Product
A6	Experiencer T40 Patient
A7	Experiencer T51 Patient
A8	Experiencer T55 Patient
A9	Experiencer T58 Patient
A10	Experiencer T48 Patient
A11	Experiencer T50 Patient
